

Katsiaryna Bykov

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8777786/publications.pdf>

Version: 2024-02-01

41
papers

1,166
citations

516215

16
h-index

395343

33
g-index

41
all docs

41
docs citations

41
times ranked

1821
citing authors

#	ARTICLE	IF	CITATIONS
1	Persistent opioid use following cesarean delivery: patterns and predictors among opioid-naïve women. <i>American Journal of Obstetrics and Gynecology</i> , 2016, 215, 353.e1-353.e18.	0.7	220
2	Safety and effectiveness of dabigatran and warfarin in routine care of patients with atrial fibrillation. <i>Thrombosis and Haemostasis</i> , 2015, 114, 1277-1289.	1.8	110
3	Eliminating Medication Copayments Reduces Disparities In Cardiovascular Care. <i>Health Affairs</i> , 2014, 33, 863-870.	2.5	84
4	Burden of Changes in Pill Appearance for Patients Receiving Generic Cardiovascular Medications After Myocardial Infarction. <i>Annals of Internal Medicine</i> , 2014, 161, 96.	2.0	74
5	Association of Gabapentinoids With the Risk of Opioid-Related Adverse Events in Surgical Patients in the United States. <i>JAMA Network Open</i> , 2020, 3, e2031647.	2.8	73
6	Type of stress ulcer prophylaxis and risk of nosocomial pneumonia in cardiac surgical patients: cohort study. <i>BMJ, The</i> , 2013, 347, f5416-f5416.	3.0	68
7	Effect of smoking on comparative efficacy of antiplatelet agents: systematic review, meta-analysis, and indirect comparison. <i>BMJ, The</i> , 2013, 347, f5307.	3.0	52
8	Pharmacy-based Interventions to Reduce Primary Medication Nonadherence to Cardiovascular Medications. <i>Medical Care</i> , 2014, 52, 1050-1054.	1.1	40
9	Confounding of the association between statins and Parkinson disease: systematic review and meta-analysis. <i>Pharmacoepidemiology and Drug Safety</i> , 2017, 26, 294-300.	0.9	39
10	Switching generic antiepileptic drug manufacturer not linked to seizures. <i>Neurology</i> , 2016, 87, 1796-1801.	1.5	35
11	Risk of mortality with concomitant use of tamoxifen and selective serotonin reuptake inhibitors: multi-database cohort study. <i>BMJ, The</i> , 2016, 354, i5014.	3.0	32
12	Thiazolidinediones and Parkinson Disease: A Cohort Study. <i>American Journal of Epidemiology</i> , 2015, 182, 936-944.	1.6	31
13	Treatment Dynamics of Newly Marketed Drugs and Implications for Comparative Effectiveness Research. <i>Value in Health</i> , 2013, 16, 1054-1062.	0.1	28
14	Non-steroidal anti-inflammatory drug administration after coronary artery bypass surgery: utilization persists despite the boxed warning. <i>Pharmacoepidemiology and Drug Safety</i> , 2015, 24, 647-653.	0.9	24
15	Impact of an Interaction Between Clopidogrel and Selective Serotonin Reuptake Inhibitors. <i>American Journal of Cardiology</i> , 2017, 119, 651-657.	0.7	21
16	Glucose-lowering medications and the risk of cancer: A methodological review of studies based on real-world data. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 2029-2038.	2.2	19
17	A Case-“Crossover”-Based Screening Approach to Identifying Clinically Relevant Drug-Drug Interactions in Electronic Healthcare Data. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 238-244.	2.3	17
18	A Unified Framework for Classification of Methods for Benefit-Risk Assessment. <i>Value in Health</i> , 2015, 18, 250-259.	0.1	16

#	ARTICLE	IF	CITATIONS
19	Clinical Outcomes of Concomitant Use of Warfarin and Selective Serotonin Reuptake Inhibitors. <i>Journal of Clinical Psychopharmacology</i> , 2017, 37, 200-209.	0.7	16
20	Coprescription of Opioids With Other Medications and Risk of Opioid Overdose. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 1011-1017.	2.3	16
21	Propensity Score Weighting Compared to Matching in a Study of Dabigatran and Warfarin. <i>Drug Safety</i> , 2017, 40, 169-181.	1.4	15
22	Generating Evidence of Clinical Outcomes of Drug-Drug Interactions. <i>Drug Safety</i> , 2017, 40, 101-103.	1.4	14
23	Adjuvant vancomycin for antibiotic prophylaxis and risk of <i>Clostridium difficile</i> infection after coronary artery bypass graft surgery. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2013, 146, 472-478.	0.4	13
24	Prevalence of Avoidable and Bias-Inflicting Methodological Pitfalls in Real-World Studies of Medication Safety and Effectiveness. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 111, 209-217.	2.3	12
25	Updating the Evidence of the Interaction Between Clopidogrel and CYP2C19-Inhibiting Selective Serotonin Reuptake Inhibitors: A Cohort Study and Meta-Analysis. <i>Drug Safety</i> , 2017, 40, 923-932.	1.4	11
26	The Case-Crossover Design for Drug-Drug Interactions. <i>Epidemiology</i> , 2019, 30, 204-211.	1.2	11
27	Bias in case-crossover studies of medications due to persistent use: A simulation study. <i>Pharmacoepidemiology and Drug Safety</i> , 2020, 29, 1079-1085.	0.9	10
28	Trends in Utilization of Prescribed Controlled Substances in US Commercially Insured Adults, 2004-2019. <i>JAMA Internal Medicine</i> , 2020, 180, 1006.	2.6	9
29	Postoperative inpatient utilization of opioid and opioid-sparing analgesics in the United States hospitals, 2007-2017. <i>Pharmacoepidemiology and Drug Safety</i> , 2021, 30, 390-394.	0.9	9
30	Comparison of Self-controlled Designs for Evaluating Outcomes of Drug-Drug Interactions. <i>Epidemiology</i> , 2019, 30, 861-866.	1.2	8
31	Evaluating Cardiovascular Health Disparities Using Estimated Race/Ethnicity. <i>Medical Care</i> , 2015, 53, 1050-1057.	1.1	7
32	Risk of Opioid Overdose Associated With Concomitant Use of Oxycodone and Selective Serotonin Reuptake Inhibitors. <i>JAMA Network Open</i> , 2022, 5, e220194.	2.8	7
33	Use of Bypassing Agents and Risk of Thromboembolic Events in Patients with Haemophilia and Inhibitors. <i>Thrombosis and Haemostasis</i> , 2017, 117, 2267-2273.	1.8	6
34	Comparative Risk of Opioid Overdose With Concomitant use of Prescription Opioids and Skeletal Muscle Relaxants. <i>Neurology</i> , 0, , 10.1212/WNL.0000000000200904.	1.5	6
35	Drug-Drug Interaction Surveillance Study: Comparing Self-Controlled Designs in Five Empirical Examples in Real-World Data. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 1353-1360.	2.3	4
36	Prospective Benefit-Risk Monitoring of New Drugs for Rapid Assessment of Net Favorability in Electronic Health Care Data. <i>Value in Health</i> , 2015, 18, 1063-1069.	0.1	3

#	ARTICLE	IF	CITATIONS
37	Comparison of Benefit-Risk Assessment Methods for Prospective Monitoring of Newly Marketed Drugs: A Simulation Study. <i>Value in Health</i> , 2015, 18, 1057-1062.	0.1	3
38	On analyzing therapeutic ineffectiveness reports. <i>Pharmacoepidemiology and Drug Safety</i> , 2013, 22, 207-208.	0.9	1
39	Impact of a Metoprolol Extended Release Shortage on Post-Myocardial Infarction β -Blocker Utilization, Adherence, and Rehospitalization. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2018, 11, e004096.	0.9	1
40	Response to "The Self-Controlled Case Series Design as a Viable Alternative to Studying Clinically Relevant Drug Interactions". <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 323-323.	2.3	1
41	Type of Oral Anticoagulant and Adverse Clinical Outcomes in Patients Extending Anticoagulation Therapy Beyond 90 Days After Hospitalization for VTE"Reply. <i>JAMA - Journal of the American Medical Association</i> , 2022, 328, 79.	3.8	0